Omega-6 vegetable oils as a driver of coronary heart disease: the oxidized linoleic acid hypothesis

James J DiNicolantonio, James H O’Keefe

The intake of omega-6 vegetable oils, particularly soybean oil, began to increase in the USA starting in the early 1900s at a time when the consumption of butter and lard was on the decline. This caused a more than two-fold increase in the intake of linoleic acid, the main omega-6 polyunsaturated fat found in vegetable oils, which now makes up around 8% to 10% of total energy intake in the Western world. The omega-6 fat linoleic acid should not be confused with conjugated linoleic acid found in pastured animal foods.

A systematic review of studies measuring the changes in linoleic acid concentration in subcutaneous adipose tissue in the USA revealed an approximate 2.5-fold increase in linoleic acid increasing from 9.1% to 21.5% from 1959 to 2008. Importantly, the concentration of linoleic acid in adipose tissue is a reliable marker of intake as the half-life of linoleic acid is approximately 2 years in adipose tissue. The authors of the study also noted that the increase in adipose tissue linoleic paralleled the increase in the prevalence of diabetes, obesity and asthma.

The amount of linoleic acid in adipose tissue, but also in platelets, is additionally positively associated with coronary artery disease (CAD), whereas long-chain omega-3 (eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) levels in platelets are inversely related to CAD. This provides rather compelling evidence that omega-3s protect whereas omega-6 linoleic acid promotes heart disease. Importantly, the increased consumption of omega-6 polyunsaturated fat linoleic acid can reduce omega-3 in the body as it competes with the alpha-linolenic acid for metabolism to longer chain polyunsaturated fats. It has been known for decades that linoleic acid, as a percentage of total fatty acids in lipids, is reduced in patients with CAD, and this has been used as an argument to suggest that low intakes of linoleic acid may cause heart disease. However, total fatty acid concentrations, as opposed to percentages, are independent of changes in other fatty acids and hence are more reliable markers of linoleic acid intake (although likely less reliable compared with adipose tissue). Importantly, linoleic acid concentrations in both serum cholesteryl esters and phospholipid fatty acids are in fact higher in patients with CAD compared with those without CAD.

The low-density lipoprotein (LDL) oxidation hypothesis gained traction during the 1980s because it was noted that in general, native unoxidised LDL does not cause foam cell formation. In other words, LDL had to become oxidised first in order for atherosclerosis to develop. Indeed, it was later discovered that oxidised LDL (oxLDL) caused direct toxic effects to the cell, recruitment and entry of monocytes into the subendothelial layer and increased foam cell formation leading to increased atherosclerosis and inflammation. Moreover, oxLDL was found to be higher in patients with CAD compared with normal patients and oxLDL was able to better identify patients at an elevated risk of heart disease. Moreover, OxLDL and autoantibodies to oxLDL are found in atherosclerotic lesions. Furthermore, patients with progressive carotid atherosclerosis have more antibodies to oxLDL versus those without progression. Thus, the evidence is resounding that oxLDL is important in
the formation of atherosclerosis. A caveat to the oxLDL hypothesis of heart disease is that oxLDL can increase on atherosclerotic plaque regression and hence an increase in oxLDL does not always suggest an increased cardiovascular risk.9

However, the oxLDL hypothesis of coronary heart disease does not get at the root cause, that is, what causes LDL to become oxidised in the first place? It was later discovered that the oxidation of LDL was initiated by the oxidation of linoleic acid contained within the LDL particles.13 15 Indeed, linoleic acid is the most common oxidised fatty acid in LDL.14 Once linoleic acid becomes oxidised in LDL, aldehydes and ketones covalently bind apoB, creating LDL that is no longer recognised by the LDL receptors in the liver but is now recognised by scavenger receptors on macrophages leading to the classic foam cell formation and atherosclerosis.13 15 16 Hence, the amount of linoleic acid contained in LDL can be seen as the true ‘culprit’ that initiates the process of oxLDL formation as it is the linoleic acid that is highly susceptible to oxidation. Additionally, an increase in the intake of linoleic acid intake increases the linoleic acid content of very-low-density lipoprotein (VLDL) and high-density lipoprotein (HDL) increasing their susceptibility to oxidise, which further increases the risk of cardiovascular disease.17–19

Thus, expanding on the oxLDL theory of heart disease, a more comprehensive theory, the ‘oxidised linoleic acid theory of coronary heart disease’, is as follows: dietary linoleic acid, especially when consumed from refined omega-6 vegetable oils, gets incorporated into all blood lipoproteins (such as LDL, VLDL and HDL) increasing the susceptibility of all lipoproteins to oxidise and hence increases cardiovascular risk.20

However, oxidised cholesterol was also considered a culprit as it was contained in atherosclerotic plaque, which led to the demonisation of dietary cholesterol as a cause of coronary heart disease (CHD). However, cholesterol bound to saturated fat does not readily oxidise; this is not the case with linoleic acid.21 Moreover, lipids from human atherosclerotic plaques have been found to contain oxidised cholesteryl linoleate (cholesterol esters containing linoleic acid).21–24 Moreover, the severity of atherosclerosis is noted to increase with increasing oxidised cholesteryl linoleate.21 25 In other words, cholesterol was protected from oxidation if bound to saturated fat but susceptible to oxidation when bound to linoleic acid. Again, this suggests that eating more linoleic acid increases the oxidation of cholesterol within LDL particles further increasing atherosclerosis formation and the risk of coronary heart disease. Indeed, healthier regions of aortas have been found to have less oxidised cholesteryl linoleate (5.8%–9.5%) compared with atherosclerotic regions (12.4%–21%).21

The most prevalent fatty acid contained in LDL is linoleic acid.14 On LDL oxidation, linoleic acid is converted to hydroperoxides, which can then be converted to hydroxy acids, such as 9-HODE (9-hydroxy-10,12-octadecadienoic acid). 9-HODE is extremely prevalent in oxidised LDL and is a good indicator of lipid peroxidation. In fact, 9-HODE is 20 times higher in young patients with atherosclerosis compared with healthy volunteers and 30-fold to 100-fold greater in patients with atherosclerosis aged 69 to 94 compared with young healthy individuals.14 9-HODE levels may be a novel way to determine someone’s cardiovascular risk and further studies should be performed to test if 9-HODE could be a good risk factor for coronary heart disease, particularly in those over the age of 50.

In 1952, Glavlind and colleagues published a paper showing that aortic lipid peroxides positively correlated with atherosclerosis.25 These findings were confirmed in 1970 by Brooks et al who found large amounts of 9-HODE and 13-hydroxy-9,11-octadecadienoic acid (13-HODE) derived from linoleic acid hydroperoxides in aortic plaques.22 In 1991, Wang and Powell found increased amounts of 9-HODE and 13-HODE in the aortas and LDL of atherosclerotic rabbits.26 That same year, Belkner and colleagues found oxygenated cholesterol esters (cholesteryl linoleate) in atherosclerotic plaques of human aortas, the degree of which correlates with the stage of atherosclerosis.27 To sum up, the increase in linoleic acid hydroperoxides in atherosclerotic plaques coincide with a greater severity of atherosclerosis versus normal regions. In other words, the more oxidised linoleic acid you have in atherosclerotic plaque, the worse the severity of CAD.

In 1987, Halliwell and Grootveld found that many diseases were hallmarked by an increase in lipid peroxidation products.27 Malondialdehyde, an oxidation product of both linoleic acid and arachidonic acid, is generally used as an indicator of lipid peroxidation as it is easier to determine compared with lipid hydroperoxides. Malondialdehyde reacts with thiobarbituric acid and forms a coloured substance of which the fluorescent intensity of the addition product can be measured. And numerous studies have found increased lipid peroxidation products, measured via thiobarbituric acid reactive substances, in patients with atherosclerosis.14

In 1984, both Steinbrecher et al and Morel et al discovered that endothelial cells can oxidise LDL and that this process involves lipid peroxidation.28 29 Oxidised LDL was found to be atherogenic and toxic to endothelial cells. In 1990, Miyazawa et al confirmed elevated levels of hydroperoxides from linoleic acid in human LDL,30 which was also elevated in human plasma.31 32 Later in 1992, it was discovered by Weiser et al that patients with atherosclerosis have more oxidised LDL versus healthy patients. Thus, numerous lines of evidence implicate the oxidation of linoleic acid as a major cause for increased oxidised LDL and hence an increased risk for coronary heart disease.

Chylomicrons and VLDL can both be acted on by lipoprotein lipase at the endothelium causing the release of harmful products such as linoleic acid free fatty acids and oxidised lipids from linoleic acid (such as 13-HODE). These oxidised linoleic acid metabolites can then induce
direct toxic effects to the endothelium such as inflammation, reactive oxygen species and adhesion molecules causing endothelial activation and permeability and a greater number of lipoproteins entering into the subendothelium leading to atherosclerosis.\(^{33,34}\) Indeed, exposure of the endothelium to linoleic acid has been found to increase LDL transfer across the endothelium, which is considered an essential step in the atherosclerosis process.\(^{35}\) This provides a novel mechanism for why marine omega-3s (EPA/DHA) may be cardioprotective considering their ability to dramatically lower triglycerides and triglyceride-rich lipoproteins such as VLDL and intermediate-density lipoprotein. Thus, marine omega-3s likely reduce the number of these lipoproteins that are acted on by endothelial lipoprotein lipase, reducing the release of harmful oxidised linoleic acid metabolites and at the same time reduce the number of these lipoproteins penetrating into the subendothelium. Box 1 provides a summary of the evidence implicating omega-6-rich vegetable oils as a causative factor in atherosclerosis and coronary heart disease.

**Clinical Studies**

**Linoleic acid increases cardiovascular events versus alpha-linolenic acid in a 2-year clinical study**

The MARGARIN study (Mediterranean Alpha linolenic enRiched Groningen dietARy Intervention study) was a randomised double-blind placebo-controlled trial tested an alpha-linolenic acid (ALA)–enriched margarine (fatty acid composition 46% LA, 15% ALA) versus a linoleic acid (LA)–enriched margarine (58% LA, 0.3% ALA) for 2 years in 103 moderately hypercholesterolaemic men and women (55 years old). Average ALA intakes were 5.9 g/day (2.3% energy) and 1.0 g/day (0.4% energy) in the ALA and LA groups, respectively. Compared with 0.3% ALA margarine (ie, the LA-enriched margarine), the 15% ALA margarine significantly lowered inflammation (C reactive protein (CRP), net difference after 1 year=−0.53 mg/L and after 2 years=−0.56 mg/L (p<0.05)) despite being given on top of a LA-rich diet. CRP was reduced after 1 year (−0.10 mg/L) but no change after 2 years in the ALA group, whereas CRP rose in the LA group (+0.2 and +0.5 mg/L, respectively). Since CRP has been independently associated with increased CV risk, this study suggests that ALA may reduce whereas LA may increase the risk of CVD.\(^{36}\) Moreover, the ALA group also had a lower plasma fibrinogen level after 1 year when using the complete MARGARIN study population (−0.18 g/L; −0.31, −0.04). Fibrinogen increased in the LA group during the 104 weeks of follow-up (0.53 g/L vs 0.32 (p=0.01)). This further suggests that LA increases whereas ALA decreases the risk of thrombosis and cardiovascular events as just a 0.18 g/L lower plasma fibrinogen level is associated with an 11% reduced risk of ischaemic heart disease.\(^{37}\) The group provided the LA-enriched margarine had a significantly improved total cholesterol (TC):HDL ratio versus the ALA-enriched margarine, despite the fact

**Box 1 Evidence implicating omega-6-rich vegetable oils as a causative factor in atherosclerosis and coronary heart disease**

1. Greater amounts of linoleic acid oxidation products are found in LDL and plasma of patients with atherosclerosis.\(^{14}\)
2. Greater amounts of linoleic acid oxidation products are found within atherosclerotic plaques and the degree of oxidation determines the severity of atherosclerosis.\(^{22}\)
3. A diet higher in oleic acid or lower in linoleic acid decreases LDL susceptibility to oxidation.\(^{14}\)
4. Endothelial cells oxidise LDL forming linoleic acid hydroperoxides.\(^{14}\)
5. Linoleic acid is the most abundant fatty acid in LDL and is extremely vulnerable to oxidation being one of the very first fatty acids to oxidise.\(^{14}\)
6. A meta-analysis of randomised controlled trials in humans found that when saturated fat plus trans-fat is replaced with omega-6 fat (high in linoleic acid), there is an increase in all-cause mortality, ischaemic heart disease mortality and cardiovascular mortality.\(^{41}\)
7. The oxidation of linoleic acid in LDL leads to conjugated dienes (malondialdehyde and 4-hydroxyenonenal), which covalently bind to apoB altering its structure creating oxidised LDL. oxLDL is no longer recognised by the LDL receptors on the liver but by scavenger receptors on macrophages causing monocyte infiltration into the subendothelium, foam cell formation and eventually atherosclerosis.\(^{14}\)
8. Oxidation products of linoleic acid (including 9-HODE and 13-HODE) are found in infarcted tissue.\(^{41}\)
9. Ultrasound of the carotid arteries in healthy patients who have high 9-HODE in LDL have signs of atherosclerosis.\(^{14}\)
10. The increase in 9-HODE begins between 40 and 50 years old prior to the clinical manifestation of atherosclerosis.\(^{14}\)
11. 9-HODE is a good indicator of oxLDL, especially if other causes of inflammation are excluded. An increased oxidised LDL, and hence levels of 9-HODE and 13-HODE in LDL, found in patients with rheumatoid arthritis may explain why they have an increased risk of heart disease.\(^{45}\)
12. 9-HODE and 13-HODE stimulate the release of interleukin 1B from macrophages.\(^{45}\)
13. The linoleic acid metabolite 9-HODE is a strong promoter of inflammation and hence may be both a marker and inducer of atherosclerosis.\(^{46}\)
14. Susceptibility of LDL to oxidation correlates independently with the extent of atherosclerosis.\(^{46}\)
15. 15) Linoleic acid free fatty acids and hydroxy acids (such as 13-HODE) can induce direct toxic effects to the endothelium causing an increase inflammation, reactive oxygen species and adhesion molecules.\(^{33,34}\)
16. Exposure of the endothelium to linoleic acid has been found to increase LDL transfer across the endothelium, an essential step in the atherosclerosis process.\(^{35}\)
17. Oxidised linoleic acid metabolites (OXLAMs) are recognised by immune cells and can recruit monocytes/ neutrophils to atherosclerotic lesions.\(^{47}\) OXLAMs are considered a danger signal activating innate immune cells, which are involved in atherosclerosis formation.\(^{48,49}\)
18. Linoleic acid is the most abundant fat found in atherosclerotic plaques, and this has been known since at least the 1960s.\(^{50}\)
19. Oxidised linoleic acid but not oxidised oleic acid is found in atherosclerotic plaques.\(^{51}\)
20. Consuming more linoleic acid increases the amount of linoleic acid in complicated aortic plaques.\(^{52}\)

**Continued**
there was an increase in cardiovascular events/deaths in those assigned to the LA-enriched margarine. Indeed, the number of strokes, myocardial infarctions and cardiovascular deaths was seven in patients given the LA-enriched margarine group versus only one in those given the ALA-enriched margarine. Thus, the intake of 6 g of ALA per day may be cardioprotective, whereas the intake of linoleic acid may increase the risk of cardiovascular disease.

A study by Mozaffarian and colleagues found that postmenopausal women with a higher saturated fat intake had less coronary atherosclerosis progression (when measured as per cent stenosis as well as minimal coronary artery diameter), whereas polyunsaturated fatty acid (PUFA) intake was associated with worsening (a decline) in the diameter of the coronary artery. For each 5% increase in energy intake from PUFA, there was a 0.17 mm greater decline in minimal coronary artery diameter and a 5.8% greater progression in mean percentage stenosis. The intake of PUFA was also associated with greater atherosclerosis progression when replacing saturated fat (p=0.02). Moreover, a greater intake of saturated fat was not associated with adverse cardiovascular outcomes (myocardial infarction (MI) or CHD death or unstable angina). In summary, the consumption of omega-6 PUFA is associated with coronary atherosclerosis progression, whereas the intake of saturated fat is associated with less plaque progression. This is in stark contrast to marine omega-3, where modest fish intake is associated with less coronary atherosclerosis progression in postmenopausal women.

The Anti-Coronary Club trial found that more people died overall and due to heart disease when saturated fat was replaced with polyunsaturated fat. Recovered data from the Sydney Diet Heart Study also found that replacement of dietary saturated fats with omega-6 linoleic acid (from safflower oil and margarine) increased all-cause mortality, cardiovascular mortality and CHD mortality. Finally, recovered data from the Minnesota Coronary Experiment indicated that replacing saturated fat with omega-6 linoleic acid (from corn oil and margarine) significantly lowered serum cholesterol but did not reduce mortality and may have increased the risk of death in older adults. In fact, for each 30 mg/dL reduction in serum cholesterol, there was a 22% higher risk of death. More troubling was a significantly greater incidence of at least one MI confirmed by autopsy in the omega-6 intervention. The overall clinical trial evidence suggests no benefit of replacing saturated fat with omega-6 polyunsaturated fat and even possible harm.

Summarising the clinical studies, Ramsden and colleagues performed a meta-analysis of randomised controlled trials comparing mixed omega-3/omega-6 PUFA to omega-6-specific PUFA compared with a combination of saturated fat and trans-fat. Both omega-3 and omega-6 were specifically increased in four data sets. When saturated fat plus trans-fat was replaced by omega-3 and omega-6, there was a significant 22% reduction in non-fatal MI plus CHD death, whereas the trials that specifically increased omega-6 caused a 13% non-significant increase. The risk of non-fatal MI plus CHD death was significantly increased in trials of increased omega-6 intake compared with trials of mixed omega-3/omega-6 PUFA (p=0.02). All-cause mortality also tended to be higher in trials of omega-6 versus saturated fat plus trans-fat (+16%). The authors concluded, “Advice to specifically increase n-6 PUFA intake, based on mixed n-3/n-6 RCT data, is unlikely to provide the intended benefits, and may actually increase the risks of CHD and death.” In an updated meta-analysis published in 2013, replacing saturated fat plus trans-fat with omega-6 PUFA was found to increase all-cause mortality as well as deaths from CHD and deaths from cardiovascular disease.

**SUMMARY**

The consumption of the omega-6 polyunsaturated fat linoleic acid has dramatically increased in the western world primarily in the form of vegetable oils. OxLDL is thought to play an important role in atherosclerosis formation; however, it is the oxidised linoleic acid contained in LDL that leads to harmful OXLAMs, which induces atherosclerosis and CHD. Thus, reducing the amount of dietary linoleic acid, mainly from industrial
vegetable/seed oils, will reduce the amount of linoleic acid in LDL and likely reduce oxLDL as well as the risk for CHD coronary heart disease.

In summary, numerous lines of evidence show that the omega-6 polyunsaturated fat linoleic acid promotes oxidative stress, oxidised LDL, chronic low-grade inflammation and atherosclerosis, and is likely a major dietary culprit for causing CHD, especially when consumed in the form of industrial seed oils commonly referred to as ‘vegetable oils’.

**Contributors** JJDN performed the literature search and wrote the initial manuscript. JHO reviewed and edited the final manuscript.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** JD is the author of The Salt Fix and Superfuel and operates the website thesaltfix.com. JHO has an ownership interest in CardioTabs, a nutraaceutical company.

**Patient consent** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correction notice** This article has been corrected since it published Online First. The second sentence in the introductory page should read as ‘This caused a more than two-fold increase in the intake of linoleic acid...’

---

**Box 2 Opposing views around linoleic acid and the risk of coronary heart disease (CHD)**

**Arguments for why linoleic acid reduces the risk of CHD**
- Reduces TC and LDL
- Increases susceptibility of LDL and other lipoproteins to oxidation
- Increases small-dense LDL
- Reduces in HDL
- Increases TGs

**Arguments for why linoleic acid increases the risk of CHD**
- Reduces in HDL
- Increases TGs

**REFERENCES**

1. Rizek RL, Friend B, Page L. Fat in todays food supply—level of use and sources. *J Am Oil Chem Soc* 1974;51:244–50.
2. Guyenet SJ, Carlson SE. Increase in adipose tissue linoleic acid of US adults in the last half century. *Adv Nutr* 2015;6:660–4.
3. Hodgson JM, Wahquist ML, Boxall JA, et al. Can linoleic acid contribute to coronary artery disease? *Am J Clin Nutr* 1993;58:228–34.
4. Schwertner HA, Mosser EL. Comparison of lipid fatty acids on a concentration basis vs weight percentage basis in patients with and without coronary artery disease or diabetes. *Clin Chem* 1993;39:659–63.
5. Gumbiner B, Low CC, Reaven PD. Effects of a monounsaturated fatty acid-enriched hypocaloric diet on cardiovascular risk factors in obese patients with type 2 diabetes. *Diabetes Care* 1998;21:9–15.
6. Silaste ML, Rantala M, Alihannan G, et al. Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a). *Arterioscler Thromb Vasc Biol* 2004;24:498–503.
7. Holvoet P, Vanhaecke J, Janssens S, et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. *Circulation* 1998;98:1487–94.
8. Holvoet P, Stassen JM, Van Cleemput J, et al. Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. *Arterioscler Thromb Vasc Biol* 1998;18:100–7.
9. Salonen JT, Ylä-Herttuala S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. *Lancet* 1992;339:883–7.
10. Ylä-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. *J Clin Invest* 1989;84:1086–95.
11. Palinski W, Ylä-Herttuala S, Rosenfeld ME, et al. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. *Arteriosclerosis* 1990;10:325–35.
12. Palinski W, Ord VA, Plump AS, et al. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. *Arteriosclerosis Thromb* 1994;14:605–16.
13. Parthasarathy S, Litvinov D, Selvarajan K, et al. Lipid peroxidation and degradation—conflicting roles in plaque vulnerability and stability. *Biochim Biophys Acta* 2008;1781:221–31.
14. Jira W, Spiteil G, Carson W, et al. Strong increase in hydroxy fatty acids derived from linoleic acid in human low density lipoproteins of atherosclerotic patients. *Chem Phys Lipids* 1988;91:1–11.
15. Haberland ME, Olch CL, Fogelman AM. Role of lysines in mediating interaction of modified low density lipoproteins with the scavenger receptor of human monocyte macrophages. *J Biol Chem* 1984;259:11305–11.
16. Haberland ME, Fogelman AM, Edwards PA. Specificity of receptor-mediated recognition of malondialdehyde-modified low density lipoproteins. *Proc Natl Acad Sci U S A* 1982;79:1712–6.
17. Young IS, McFarlane C, McEnery J. Oxidative modification of triacylglycerol-rich lipoproteins. *Biochem Soc Trans* 2003;31(Pt 5):1082–6.
18. Francis GA. High density lipoprotein oxidation: in vitro susceptibility and potential in vivo consequences. *Biochim Biophys Acta* 2000;1483:217–35.
19. Shao B, Oda MN, Vaisar T, et al. Pathways for oxidation of high-density lipoprotein in human cardiovascular disease. *Curr Opin Mol Ther* 2006;8:198–205.
20. Reaven P, Parthasarathy S, Grasse BJ, et al. Effects of oleate-rich and linoleate-rich diets on the susceptibility of low density lipoprotein to oxidative modification in mildly hypercholesterolemic subjects. *J Clin Invest* 1993;91:668–76.
21. Belkner J, Wiesner R, Kühn H, et al. The oxygenation of cholesterol esters by the reticulocyte lipoxigenase. *FEBS Lett* 1991;279:110–4.
22. Brooks CJ, Harland WA, Steel G, et al. Lipids of human atheroma: isolation of hydroxycarboxylic acidic acids from advanced aortal lesions. *Biochim Biophys Acta* 1970;202:563–6.
23. Harland WA, Gilbert JD, Steel G, et al. Lipids of human atheroma. 5. The occurrence of a new group of polar sterol esters in various stages of human atherosclerosis. *Atherosclerosis* 1971;13:239–46.
24. Brooks CJ, Steel G, Gilbert JD, et al. Lipids of human atheroma. 6. Characterisation of a new group of polar sterol esters from human atherosclerotic plaques. *Atherosclerosis* 1971;13:223–37.
25. Glavind J, Hartmann S, Clemenzen J, et al. Studies on the role of lipoperoxides in human pathology. II. The presence of peroxided lipids in the atherosclerotic aorta. *Acta Pathol Microb Scand* 1952;30:1–6.
26. Wang T, Powell WS. Increased levels of monohydroxy metabolites of arachidonic acid and linoleic acid in LDL and aorta from atherosclerotic rabbits. *Biochim Biophys Acta* 1991;1084:129–38.
27. Halliwell B, Grootveld M. The measurement of free radical reactions in humans. Some thoughts for future experimentation. *FEBS Lett* 1987;213:9–14.
28. Steinbrecher UP, Parthasarathy S, Leake DS, et al. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. *Proc Natl Acad Sci U S A* 1984;81:3883–7.
29. Morel DW, DICorleto PE, Chisom GM. Endothelial and smooth muscle cells after low density lipoprotein in vitro by free radical oxidation. *Arteriosclerosis* 1984;4:357–64.
30. Miyazawa T, Fujimoto K, Okawa S. Determination of lipid hydroperoxides in low density lipoprotein from human plasma using high performance liquid chromatography with chemiluminescence detection. *Biomed Chromatogr* 1990;4:131–4.
31. Miyazawa T. Determination of phospholipid hydroperoxides in human blood plasma by a chemiluminescence-HPLC assay. *Free Radic Biol Med* 1989;7:209–18.
32. Miyazawa T, Yasuda K, Fujimoto K, et al. Presence of phosphatidylcholine hydroperoxide in human plasma. J Biochem 1988;106:744–6.
33. Wang L, Gill R, Pedersen TL, et al. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. Lipid Res 2009;50:504–13.
34. Elisein L, Wilson DW, Lamé MW, et al. Lipolysis products from triglyceride-rich lipoproteins increase endothelial permeability, perturb zonula occludens-1 and F-actin, and induce apoptosis. Am J Physiol Heart Circ Physiol 2007;292:H15–53.
35. Heusser B, Shabestari D, Specter AA. Exposure to fatty acid increases human low density lipoprotein transfer across cultured endothelial monolayers. Circ Res 1985;57:776–80.
36. Bemelmans WJ, Lefrandt JD, Feskens EJ, et al. Increased alpha-linolenic acid intake lowers C-reactive protein, but has no effect on markers of atherosclerosis. Eur J Clin Nutr 2004;58:1083–9.
37. Bemelmans WJ, Broer J, Feskens EJ, et al. Effect of an increased intake of alpha-linolenic acid and group nutritional education on cardiovascular risk factors: the Mediterranean Alpha-Linolenic Enriched Groningen Dietary Intervention (MARGARIN) study. Am J Clin Nutr 2002;75:221–7.
38. Mozaffarian D, Rimm EB, Herrington DM. Dietary fats, carbohydrate, and progression of coronary atherosclerosis in postmenopausal women. Am J Clin Nutr 2004;80:1176–84.
39. Erkkiä AT, Lichtenstein AH, Mozaffarian D, et al. Fish intake is associated with a reduced progression of coronary artery atherosclerosis in postmenopausal women with coronary artery disease. Am J Clin Nutr 2004;80:626–32.
40. Christakis G, Rinzler SH, Archer M, et al. Effect of the anti-coronary cell inflammation, coronary heart disease. Risk-factor status. JAMA 1966;198:507–604.
41. Ramsden CE, Zamora D, Leerarthaepin B, et al. Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ 2013;346:e8707.
42. Ramsden CE, Zamora D, Majchrzak-Hong S, et al. Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73). BMJ 2016;353:i1246.
43. Ramsden CE, Hibbeln JR, Majchrzak SK, et al. n-6 fatty acid-specific and mixed polysaturated dietary interventions have different effects on CHD risk: a meta-analysis of randomised controlled trials. Br J Nutr 2010;104:1586–600.
44. Dudda A, Spiteiller G, Kobelt F. Lipid oxidation products in ischemic porcine heart tissue. Chem Phys Lipids 1996;82:39–51.
45. Jira W, Spiteiller G, Richter A. Increased levels of lipid oxidation products in low density lipoproteins of patients suffering from rheumatoid arthritis. Chem Phys Lipids 1997;87:81–9.
46. Regnstrom J, Nilsson J, Tornvall P, et al. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 1992;339:1183–6.
47. Rolin J, Vego H, Maghazachi AA. Oxidized lipids and lysophosphatidylcholine induce the chemotaxis, up-regulate the expression of CR3 and CXCR4 and abrogate the release of IL-6 in human monocytes. Toxins 2014;6:2840–56.
48. Binder CJ. Naturally occurring IgM antibodies to oxidation-specific epitopes. Adv Exp Med Biol 2012;750:2–13.
49. Rolin J, Al-Jaden Z, Maghazachi AA. Oxidized lipids and lysophosphatidylcholine induce the chemotaxis and intracellular calcium influx in natural killer cells. Immunobiology 2013;218:875–83.
50. Lawrie TD, McAlpine SG, Riffkind BM, et al. A comparison of serum lipoprotein and aortic plaque fatty acids. Clin Sci 1964;27:89–96.
51. Carpenter KL, Taylor SE, Ballantine JA, et al. Lipids and oxidised lipids in human atheroma and normal aorta. Biochim Biophys Acta 1993;1167:121–30.
52. Dayton S, Hashimoto S, Pearce ML. Influence of a diet high in unsaturated fat upon composition of arterial tissue and atheromatoma in man. Circulation 1965;32:911–24.
53. Wan JB, Huang LL, Rong R, et al. Endogenously decreasing tissue n-6/n-3 fatty acid ratio reduces atherosclerotic lesions in apolipoprotein E-deficient mice by inhibiting systemic and vascular inflammation. Arterioscler Thromb Vasc Biol 2010;30:2487–94.
54. Wang HH, Hung TM, Wei J, et al. Fish oil increases antioxidant enzyme activities in macrophages and reduces atherosclerotic lesions in apoE-knockout mice. Cardiovasc Res 2004;61:169–76.
55. Thies F, Garry JM, Yaqoob P, et al. Association of n-3 polysaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003;361:477–85.
56. Marchix J, Choque B, Koubra M, et al. Excessive dietary linoleic acid induces proinflammatory markers in rats. J Nutr Biochem 2015;26:1434–41.
57. Hennig B, Meeranari P, Ramdass P, et al. Fatty acid-mediated activation of vascular endothelial cells. Metabolism 2000;49:1006–13.
58. Toborek M, Hennig B. The role of linoleic acid in endothelial cell gene expression. Relationship to atherosclerosis. Subcell Biochem 1998;30:141–55.
59. Toborek M, Lee YY, Garrido R, et al. Unsaturated fatty acids selectively induce an inflammatory environment in human endothelial cells. Am J Clin Nutr 2002;75:119–25.
60. Harrell MD, Stimers JR. Differential effects of linoleic acid metabolites on cardiac sodium current. J Pharmacol Exp Ther 2002;303:347–55.
61. Luostarinen R, Boberg M, Saldeen T. Fatty acid composition in total phospholipids of human coronary arteries in sudden cardiac death. Atherosclerosis 1993;99:187–93.
62. Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. Arterioscler Thromb 1992;12:911–9.
63. Parthasarathy S, Khoo JC, Miller E, et al. Low density lipoprotein rich in oleic acid is protected against oxidative modification: implications for dietary prevention of atherosclerosis. Proc Natl Acad Sci U S A 1990;87:3894–8.
64. Hartwich J, Malec MM, Partyka L, et al. The effect of the plasma n-3/n-6 polysaturated fatty acid ratio on the dietary LDL phenotype transformation—in insights from the LIPGENE study. Clin Nutr 2009;28:510–5.
65. Griffin MD, Sanders TA, Davies IG, et al. Effects of altering the ratio of dietary n-6 to n-3 fatty acids on insulin sensitivity, lipoprotein size, and postprandial lipemia in men and postmenopausal women aged 45–70 y: the OPTILIP Study. Am J Clin Nutr 2006;84:1290–8.
66. Nilsen DW, Alfretksen G, Landmark K, et al. Effects of a high-dose concentrate of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. Am J Clin Nutr 2001;74:50–6.